Consistent with the current results, available evidence from previous studies suggest that myelin alterations occur early in the development of tau pathology: Lower MRI-assessed myelin water fraction in the WM was associated with higher CSF biomarker levels of phospho-tau in preclinical AD [12], and post-mortem assessed myelin-specific ceramide levels were reduced in early Braak-stage region of tau pathology including the medial temporal lobe [10]. This evidence concerns the gene MAPT and Alzheimer disease.